Roger Mills has joined Addex Therapeutics Ltd as chief medical officer (CMO), a newly created position that will support the company’s clinical-stage compounds for neurological diseases. Dr Mills was most recently CMO at Acadia Pharmaceuticals Inc where he oversaw the late-stage development and approval of a new drug for Parkinson’s disease psychosis. Addex’s lead product is being developed for dyskinesia associated with Parkinson’s disease.
Dr Mills holds a medical degree from Imperial College, Charing Cross Hospital Medical School, London, UK. He is currently a visiting professor at the Centre for Age Related Diseases at King’s College London.
Addex announced the appointment on 28 November 2016.
Copyright 2016 Evernow Publishing Ltd